MediWound (NASDAQ:MDWD) Releases Earnings Results, Beats Estimates By $0.04 EPS

MediWound (NASDAQ:MDWD) issued its quarterly earnings data on Thursday. The biopharmaceutical company reported ($0.56) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.60) by $0.04, FiscalAI reports. The firm had revenue of $1.87 million during the quarter, compared to analysts’ expectations of $2.09 million. MediWound had a negative return on equity of 62.11% and a negative net margin of 98.43%.

Here are the key takeaways from MediWound’s conference call:

• EscharEx phase 3 VALUE trial is actively enrolling toward a 216‑patient target across ~40 U.S./EU sites with a pre‑specified interim assessment and expected enrollment completion by year‑end 2026, and the company plans a phase 2 diabetic foot ulcer study plus an investigator pressure‑ulcer study in H2 2026 with multiple industry collaborators (e.g., B. Braun).
• The expanded NexoBrid manufacturing facility is operational and boosts production capacity sixfold, with commercial release pending regulatory clearances expected in 2026 and management prioritizing support for burn‑center adoption and national stockpiling/military preparedness.
• 2025 revenue declined to $17.0M (Q4 $1.9M) and operating/adjusted EBITDA losses widened as R&D rose to $14.3M to fund EscharEx, with the shortfall driven primarily by a U.S. government shutdown and lower product sales to Vericel.
• The balance sheet was strengthened to $53.6M in cash following a $30M registered direct offering and warrant exercises, and management reaffirmed multi‑year revenue guidance ($24–26M in 2026; $32–35M in 2027; $50–55M in 2028), while noting these forecasts assume BARDA/DoD support.

MediWound Stock Down 0.9%

NASDAQ:MDWD traded down $0.16 on Thursday, reaching $17.44. 34,875 shares of the company’s stock were exchanged, compared to its average volume of 106,931. The business has a fifty day moving average of $17.76 and a 200-day moving average of $17.87. The firm has a market capitalization of $223.39 million, a price-to-earnings ratio of -9.18 and a beta of 0.13. MediWound has a 52-week low of $14.14 and a 52-week high of $22.50.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on the stock. Wall Street Zen raised shares of MediWound from a “sell” rating to a “hold” rating in a report on Saturday, November 22nd. Zacks Research raised shares of MediWound from a “strong sell” rating to a “hold” rating in a report on Tuesday, November 11th. Weiss Ratings reissued a “sell (d-)” rating on shares of MediWound in a report on Thursday, January 22nd. Finally, HC Wainwright reissued a “buy” rating and set a $36.00 target price (up from $31.00) on shares of MediWound in a research note on Friday, November 21st. Three equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, MediWound presently has a consensus rating of “Hold” and a consensus target price of $31.67.

Institutional Trading of MediWound

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Quarry LP purchased a new stake in MediWound in the fourth quarter valued at $26,000. BNP Paribas Financial Markets raised its position in MediWound by 90.4% in the 3rd quarter. BNP Paribas Financial Markets now owns 1,523 shares of the biopharmaceutical company’s stock valued at $27,000 after purchasing an additional 723 shares during the last quarter. Russell Investments Group Ltd. grew its holdings in shares of MediWound by 69.1% during the second quarter. Russell Investments Group Ltd. now owns 1,588 shares of the biopharmaceutical company’s stock worth $31,000 after buying an additional 649 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in MediWound by 22.4% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 5,452 shares of the biopharmaceutical company’s stock valued at $85,000 after acquiring an additional 999 shares during the period. Finally, MetLife Investment Management LLC acquired a new position in MediWound in the 4th quarter valued at about $109,000. Institutional investors and hedge funds own 46.83% of the company’s stock.

About MediWound

MediWound Ltd. (NASDAQ: MDWD) is a biopharmaceutical company headquartered in Yavne, Israel, specializing in the development and commercialization of innovative enzymatic therapies for burn and wound management. Since its establishment, the company has focused on advancing proteolytic enzyme technology to address critical needs in debridement and tissue repair. MediWound operates research and development facilities in Israel and maintains commercial offices in the United States to support its global market presence.

The company’s lead product, NexoBrid®, is an enzyme-based debriding agent designed to selectively remove burn eschar without harming viable tissue.